Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 1-2 weeks | |
50 mg | $1,980 | 1-2 weeks | |
100 mg | $2,500 | 1-2 weeks |
Description | Ivacaftor hydrate is an orally bioavailable CFTR potentiator. It also is used for cystic fibrosis treatment. |
In vitro | Ivacaftor displays no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor enhances the chloride secretion (EC50 of 0.236 ± 0.200 μM). Compared to the F508del HBEs, it has a 10-fold shift in potency [3]. Ivacaftor (10?μM) enhances the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants[1]. Ivacaftor (10 μM) obviously increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells[2]. VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation, in recombinant cells. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4]. |
In vivo | In rat, Ivacaftor (1-200 mg/kg, p.o.) shows good oral bioavailability[3]. |
Alias | VX-770 hydrate |
Molecular Weight | 410.514 |
Formula | C24H30N2O4 |
Cas No. | 1134822-07-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.